Votre profil :Grand public|Professionnel|Étudiant|Entreprises / Collectivités|Journaliste
Programme CAPTOR
Investissements d'avenir
Pharmacologie sociale (WP3)Publications

Publications

Document(s) 1 à 8 sur 24 Suivant > >>
Trier par nom
 
Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics (2017)
Auteur(s): Patras de Campaigno, E.; Bondon-Guitton, E.; Laurent, G.; Montastruc, F.; Montastruc, J. L.; Lapeyre-Mestre, M.; Despas, F.;

Br J Clin Pharmacol.
ISBN: 1365-2125 (Electronic) 0306-5251 (Linking). DOI: 10.1111/bcp.13238.

AIMS: The aims of the present study were to evaluate the risk of cardiac failure (CF) associated with 15 anticancer protein kinase inhibitors (PKIs) through a case/noncase analysis and to identify which PK(s) and pathways are involved in PKI-induced CF. METHODS: In order to evaluate ...

 En savoir plus


Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database (2017)
Auteur(s): Palmaro, A.; Rouge-Bugat, M. E.; Gauthier, M.; Despas, F.; Moulis, G.; Lapeyre-Mestre, M.;

Pharmacoepidemiol Drug Saf.
ISBN: 1099-1557 (Electronic) 1053-8569 (Linking). DOI: 10.1002/pds.4180.

PURPOSE: The risk of venous thromboembolic event (VTE) in multiple myeloma is particularly increased. Current guidelines recommend systematic VTE prophylaxis with vitamin K antagonists (VKA) or low weight molecular heparin (LWMH) or unfractionated heparin (UFH) in high-risk pat...

 En savoir plus


Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report (2016)
Auteur(s): Tournaire, G.; Despas, F.; Huguet, F.; Montastruc, J. L.; Bondon-Guitton, E.;

J Clin Pharm Ther. 41. 3. 360-361.
ISBN: 1365-2710 (Electronic) 0269-4727 (Linking). DOI: 10.1111/jcpt.12383.

WHAT IS KNOWN AND OBJECTIVE: Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had prev...

 En savoir plus


Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy (2016)
Auteur(s): Tavitian, S.; Denis, A.; Vergez, F.; Berard, E.; Sarry, A.; Huynh, A.; Delabesse, E.; Luquet, I.; Huguet, F.; Recher, C.; Bertoli, S.;

Am J Hematol. 91. 2. 193-198.
ISBN: 1096-8652 (Electronic) 0361-8609 (Linking). DOI: 10.1002/ajh.24228.

We assessed the influence of obesity on the characteristics and prognosis of acute myeloid leukemia (AML). Indeed, safety of intensive chemotherapy and outcome of obese AML patients in a real-life setting are poorly described, and chemotherapy dosing remains challenging. ...

 En savoir plus


Drug-drug interactions with imatinib: An observational study (2016)
Auteur(s): Recoche, I.; Rousseau, V.; Bourrel, R.; Lapeyre-Mestre, M.; Chebane, L.; Despas, F.; Montastruc, J. L.; Bondon-Guitton, E.;

Medicine (Baltimore). 95. 40. e5076.
ISBN: 1536-5964 (Electronic) 0025-7974 (Linking). DOI: 10.1097/MD.0000000000005076.

Many patients treated with imatinib, used in cancer treatment, are using several other drugs that could interact with imatinib. Our aim was to study all the drug-drug interactions (DDIs) observed in patients treated with imatinib.We performed 2 observational s...

 En savoir plus


Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies (2016)
Auteur(s): Palmaro, A.; Moulis, G.; Despas, F.; Dupouy, J.; Lapeyre-Mestre, M.;

Fundam Clin Pharmacol. 30. 6. 616-624.
ISBN: 1472-8206 (Electronic) 0767-3981 (Linking). DOI: 10.1111/fcp.12214.

In this study, we aimed to provide an updated overview of drug data contained in the French health insurance database (SNIIRAM) and its associated national representative sample (EGB). This study identified most common problems concerning drug data: (i) change in level...

 En savoir plus


The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study (2016)
Auteur(s): Lamy, S.; Bettiol, C.; Grosclaude, P.; Compaci, G.; Albertus, G.; Recher, C.; Nogaro, J. C.; Despas, F.; Laurent, G.; Delpierre, C.;

BMC Health Serv Res. 16. a. 336.
ISBN: 1472-6963 (Electronic) 1472-6963 (Linking). DOI: 10.1186/s12913-016-1553-9.

BACKGROUND: Healthcare providers-related disparities in adherence to the treatment plan among lymphoma patients are found even in a universal healthcare system, but the mechanism remains unclear. We investigated the association between the type of care center and th...

 En savoir plus


Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database (2016)
Auteur(s): Conte, C.; Rueter, M.; Laurent, G.; Bourrel, R.; Lapeyre-Mestre, M.; Despas, F.;

Support Care Cancer. 24. 11. 4791-4799.
ISBN: 1433-7339 (Electronic) 0941-4355 (Linking). DOI: 10.1007/s00520-016-3331-y.

PURPOSE: Patients with B cell non-Hodgkin's lymphomas (B-NHLs) are known to be at risk of developing psychological disorders. The aims of this study were to measure the incidence of psychotropic drug use during the diagnosis and the active treatment phase in ...

 En savoir plus


Document(s) 1 à 8 sur 24 Suivant > >>
Version mobile CAPTOR - Médicaments anti cancerCAPTOR - Médicaments anti cancer
 
Agenda

Réunion CAPTOR WP3
Faculté de Médecine de Purpan - 17:30 - 22/03/2017

EACE 30th Annual Scientific Meeting
IUCT-Oncopole - 26-27-28/04/2017
Université Toulouse 3 - Paul Sabatier Inserm CNRS Institut Claudius Regaud CHU de Toulouse IUC Oncopole ANR